GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tellgen 300642.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

16.15

+0.81%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tellgen

Its shares trade on Shenzhen under the ticker 300642.SZ. It has been listed since 21 April 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥363.8m and net income of CN¥3.6m. At that date it held total assets of CN¥2.06bn and shareholders' equity of CN¥1.43bn.

Tellgen Corp. engages in the developing, manufacturing and marketing of molecular diagnostic products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2017-04-21. The firm's products are comprised of immunodiagnostic products, molecular diagnostic products and biochemical diagnostic products, including tumor marker detection products, human papillomavirus (HPV) nucleic acid testing products, autoimmune disease detection products and lung cancer methylation mutation detection products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
21 Apr 2017
Employees
710
Website
tellgen.com ↗

Leadership

Pay as last reported

  • Mr. Jian'er YaoChairman of the Board, General Manager, since 2015
  • Mr. Songtao LiFinance Director
  • Mr. Xiaoqing WangDeputy General Manager, Secretary of the Board, Director, since 2016
  • Mr. Enhuai YangDeputy General Manager, Director, since 2020
  • Mr. Ye ShengDeputy General Manager
  • Mr. Zhangfu YuDirector
  • Mr. Shaoxiong ChenIndependent Director
  • Mr. Wei YuIndependent Director
  • Mr. Jiaxiang ZhaoIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tellgen Corp employs 710 full-time employees in Shanghai, China.
  • Tellgen Corp develops molecular diagnostic products including HPV nucleic acid testing.
  • Tellgen Corp's products include tumor marker detection and lung cancer methylation mutation detection.

Weaknesses

  • Tellgen Corp's headquarters is in Shanghai, China, with no other locations mentioned.
  • Tellgen Corp's IPO was on 21 April 2017, a fixed date with no recent updates.
  • Tellgen Corp's business is limited to molecular diagnostic products without expansion details.

Opportunities

  • Tellgen Corp can expand its molecular diagnostic product line in the Chinese market.
  • Tellgen Corp's immunodiagnostic products have potential in the global Health Care sector.
  • Tellgen Corp's biochemical diagnostic products could grow in the Chinese Health Care market.

Threats

  • Tellgen Corp faces competition from other Health Care companies in China.
  • Tellgen Corp's products are limited to specific diagnostic areas without broader market reach.
  • Tellgen Corp's business relies on a single sector, Health Care, increasing vulnerability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.